ArticleCureus2025
Transnasal Endoscopic Resection of a Pituitary Metastasis From a Tonsillar Squamous Cell Carcinoma (SCC): A Case Report and a Review of the Literature.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pituitary metastasis as the first sign of distant spread in mandibular squamous cell carcinoma.Journal of surgical case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This article presents the first documented case of a 61-year-old patient who underwent radical transnasal transsphenoidal endoscopic resection of a pituitary metastasis from a squamous cell carcinoma (SCC) of the tonsils. Only two other cases of pituitary metastases in SCC have been described in the literature to date. The patient was diagnosed with p16 and human papillomavirus (HPV)-positive tonsillar SCC in June 2022. After initial radiotherapy and cisplatin-based chemotherapy, the patient had to undergo repeat surgeries due to local tumor recurrence. At that time, there was no evidence of metastatic disease. In August 2024, 26 months after the initial diagnosis, the patient presented to another institution with severe headaches, dizziness, nocturia, and pollakiuria. Laboratory tests revealed panhypopituitarism as well as diabetes insipidus. Magnetic resonance imaging (MRI) showed an intra- and suprasellar mass with increased F-fluoro-2-deoxy-D-glucose (FDG) uptake on positron emission tomography/computed tomography (PET/CT). A transcranial biopsy was performed that confirmed the diagnosis of a pituitary metastasis. Since radiotherapy carried a significant risk of impacting the unaffected optical system and the effect of chemotherapy was unknown, the interdisciplinary tumor board decided on resection. The patient underwent an extended endoscopic endonasal approach for radical tumor removal. The postoperative course was uneventful, and the patient received adjuvant radiochemotherapy and pituitary hormone replacement. Postoperative chemotherapy and radiation led to progression of the underlying disease, and the patient had to be switched to best supportive care six months after surgery. This is the first case that reports the feasibility of a radical resection of a pituitary metastasis of SCC via the endoscopic endonasal approach. This paper reviews the risk factors, radiographic presentation, treatment, and follow-up of patients with pituitary metastases from oropharyngeal cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.